Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protoc... by Sander W Tas, Joost Raaphorst, Paco M J Welsing, Jacob M van Laar, Rogier M Thurlings, Robbert J Goekoop, César Magro Checa, Jan A M van Laar, Bettina C Geertsema-Hoeve, Nicolle H Rekers, Erik Present

Get full text

Interleukin-6 in synovial fluid drives the conversion of DC2s to DC3s in inflammatory arthritis by Annika H. Decker, Lucas L. van den Hoogen, Tom van Oorschot, Liliana Sanchez-Rocha, Martine A. Boks, Ghaith Bakdash, Ranjeny Thomas, Calin D. Popa, Martijn Verdoes, Rogier M. Thurlings, Anouk M.D. Becker, I. Jolanda M. de Vries

Get full text